Related Experiment Video
Updated: Feb 13, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2
Laura F Mortan1,2, Zitha Redempta Isingizwe1,3, Doris Mangiaracina Benbrook1,2,3
1Gynecologic Oncology Section, Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.
Background:
Our objective was to identify and validate proteins that predict which patients with ovarian cancer will respond to SHetA2, an investigational drug in a phase 1 trial for patients with advanced or recurrent solid tumors (clinicaltrials.gov: NCT04928508).
Methods:
Cells were cultured from ascites from nine consented patients under an institutional review board-approved protocol. SHetA2 or olaparib sensitivities were determined using metabolic viability assays in ascites-derived cultures or ovarian cancer cell lines. Expression of four SHetA2 target proteins and sixteen proteins previously identified in an ovarian cancer mouse model were measured using microcapillary electrophoresis. Triosephosphate isomerase 1 (TPI1) was modulated by siRNA or lentivirus vector-mediated overexpression. Metabolites were measured using mass spectrometry.
Results:
TPI1 was elevated in SHetA2-sensitive compared to SHetA2-resistant ascites-derived cultures (two-way ANOVA q-value = 0.0003). The majority of (5/9) cultures were olaparib-resistant and SHetA2-sensitive. TPI1 was higher in olaparib-resistant cultures (two-way ANOVA q-value = 0.0003). Reduction in or overexpression of TPI1 reduced or increased SHetA2 potency, respectively, in two ovarian cancer cell lines (t-tests; p < 0.05). SHetA2 reduced the metabolites in glycolysis downstream of TPI1, the tricarboxylic acid cycle and oxidative pentose phosphate pathway.
Conclusions:
TPI1 is a candidate functional biomarker of SHetA2 sensitivity in ovarian cancer.
Insights
Triosephosphate isomerase 1 (TPI1) predicts ovarian cancer response to SHetA2. Higher TPI1 levels correlated with sensitivity, and modulating TPI1 affected drug potency, identifying TPI1 as a potential biomarker.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Identifying predictive biomarkers for investigational cancer drugs is crucial for personalized treatment.
- SHetA2 is an investigational drug undergoing phase 1 trials for advanced or recurrent solid tumors.
- Understanding patient response to SHetA2 in ovarian cancer requires biomarker discovery.
Purpose of the Study:
- To identify and validate protein biomarkers predicting ovarian cancer patient response to SHetA2.
- To investigate the role of Triosephosphate isomerase 1 (TPI1) in SHetA2 sensitivity.
Main Methods:
- Ascites-derived ovarian cancer cell cultures were used to assess sensitivity to SHetA2 and olaparib.
- Protein expression (including TPI1) was measured using microcapillary electrophoresis.
- TPI1 levels were modulated via siRNA and lentivirus vectors; metabolite analysis was performed using mass spectrometry.
Main Results:
- Elevated TPI1 levels were significantly associated with SHetA2 sensitivity in ovarian cancer ascites-derived cultures (q-value = 0.0003).
- The majority of cultures were olaparib-resistant yet SHetA2-sensitive, with higher TPI1 in olaparib-resistant cases.
- Modulating TPI1 expression directly impacted SHetA2 drug potency in ovarian cancer cell lines (p < 0.05).
- SHetA2 treatment altered downstream metabolites in glycolysis, the TCA cycle, and the pentose phosphate pathway.
Conclusions:
- Triosephosphate isomerase 1 (TPI1) is a strong candidate biomarker for predicting SHetA2 sensitivity in ovarian cancer.
- TPI1's functional role in metabolic pathways affected by SHetA2 supports its utility as a biomarker.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
Related Concept Videos
Reliability and Validity
Energy-requiring Steps of Glycolysis
Data Validation
Key parameters for method validation include:
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Ovarian Cycle
Functional Groups